《新股表現》達力普(01921.HK)暗盤開報1.5元 低上市價5.7%
根據輝立交易平台顯示,明天掛牌的達力普控股(01921.HK)暗盤低開5.7%報1.5元獲承接,最高見1.59元,現造1.53元,較上市價1.59元,低3.8%,成交18萬股。
達力普是私營製造商中一間領先的石油專用管製造商,擁有全產業鏈業務模式,提供包括開發、製造和銷售石油專用管及其他石油管全面性服務,主要供應予內地的石油公司、石油專用管製造商及石油專用管加工廠。是次上市共發售3億股,其中10%公開發售獲1.5倍超購,認購一手中籤率60%;股份以招股範圍(1.59-1.83元)下限定價,料集資淨額4.26億元,大部分用作為二期廠房擴張提供資金。上市獨家保薦人民銀資本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.